Introduction
The use of ABO-incompatible donor organs is a possible solution for the shortage of donor organs for transplantation; however, naturally occurring Abs against blood group A or B (A/B) carbohydrate determinants in sera are a major impediment to achieving successful transplantation. Transplantation across ABO blood barriers using living donor organs has been performed with some success. 1, 2 Removing anti-A/B antibodies (Abs) by plasma exchange or plasmapheresis, splenectomy, and use of anti-B-cell immunosuppressants in the recipients are widely adopted strategies to avoid Ab-dependent rejection of ABO-incompatible organ grafts. [3] [4] [5] [6] [7] [8] Despite the use of such therapeutic methods, graft survival in ABO-incompatible organ transplantation is generally inferior compared with that in ABO-compatible transplantation because of the reappearance of anti-A/B Abs. 1, 4, [9] [10] [11] [12] The specific and persistent inhibition of anti-A/B Ab production might be necessary for completely preventing anti-A/B Ab-mediated rejection; however, a method for either elimination or suppression of B-cell clones responding to the A/B carbohydrates has not yet been established.
Using surface staining with fluorescein-labeled synthetic A carbohydrates conjugated to bovine serum albumin (BSA), we previously demonstrated that B cells with surface immunglobulin M (sIgM) receptors for blood group A carbohydrate determinants are found exclusively in a small but nevertheless significant B-cell subpopulation (ie, sIgM ϩ CD11b ϩ CD5 ϩ B-1 cells) in blood group O or B human peripheral blood. 13 Anti-A-specific human Abs were detected in the sera of nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice that received blood group O human peripheral blood mononuclear cells (PBMCs) containing B cells with anti-A receptors. In contrast, these Abs were not detected in sera from NOD/SCID mice that received blood group A human PBMCs devoid of such B cells. This suggests that the B-1 cells with anti-A receptors comprise cells actively producing anti-A Abs and/or precursors of such cells. CD11b ϩ CD5 ϩ B-1 cells differ from the more abundant conventional CD11b Ϫ CD5 Ϫ B-2 cells in many aspects that presumably reflect their different roles in the immune system. In addition to their differences in the cell-surface phenotypes, both these cells possess characteristics that suggest that they are antigen (Ag) specific. Previous reports indicated that B-1 cell differentiation occurs through Ig gene rearrangement following stimulation with certain Ags, particularly thymusindependent type 2 (TI-2) Ags. [14] [15] [16] [17] Furthermore, cyclosporin A (CsA), which is widely and satisfactorily used to prevent T-cellmediated rejection of allografts, is reported to block such differentiation. 18 However, anti-A/B Ab levels are known to rapidly increase in the sera of patients receiving an ABO-incompatible organ, even on CsA therapy. This discrepancy may be explained by the possibility that CsA has no effect on cells that are actively producing Abs, or on cells that have already differentiated to B-1 cells. In this case, the specific elimination of both Ab-producing cells and differentiated B-1 cells with anti-A/B specificity as well as subsequent CsA therapy might lead to lasting inhibition of anti-A/B Ab production following ABO-incompatible organ transplantation. Since we previously reported that both Ab (IgM)-producing cells and B-1 cells express sIgM B-cell receptors (BCRs), which can bind specific Ags, 19 these cells with anti-A/B receptors may be targeted for specific elimination by using synthetic A/B carbohydrates conjugated with a cytotoxic constituent. The administration of these carbohydrates into the circulation may result in their specific binding to the corresponding BCRs, consequently depleting these B cells via their interaction with the cytotoxic constituent without affecting B-cell clones with other Ab specificities.
The present study has proved that normal mice have B cells with anti-A receptors, which show the sIgM ϩ CD11b ϩ CD5 ϩ B-1 phenotype, and naturally occurring Abs against human blood group A carbohydrates are detectable in their sera, resembling human blood group O or B individuals. We therefore used such mice for investigating the effects of a novel approach consisting of treatment with synthetic A carbohydrates and CsA on B cells responding to blood group A Ags.
Materials and methods

Mice
Female Balb/c mice, aged 12 weeks, were purchased from Clea Japan (Osaka, Japan) and housed in the animal facility of Hiroshima University in a specific pathogen-free microisolator environment. The animal experiments were approved by the Institutional Review Board of Hiroshima University and conducted in accord with the guidelines of the National Institutes of Health (NIH publication No. 86-23, revised 1985).
In vivo immunization
Fresh human peripheral blood collected from blood group A volunteers was irradiated at 30 Gy to deplete white blood cells (WBCs). Informed consent was obtained in accordance with the Declaration of Helsinki from all volunteers. A suspension of 5 ϫ 10 8 human blood group A red blood cells (A-RBCs) in 1 mL phosphate-buffered saline (PBS) was injected into the peritoneal cavity of each mouse.
Flow cytometry analysis for detecting B cells with receptors for blood group A carbohydrate determinants
Single-cell suspensions were prepared from homogenized spleen (Spl) of mice using erythrocyte-lysing solution (155 mM NH 4 Cl, 10 mM KHCO 3 , 1 mM EDTA-2Na, and PBS [pH 7.4]). Peritoneal cavity (PerC) cells were isolated by peritoneal lavage using cold PBS. To detect B cells with receptors for human blood group A trisaccharide, 5(6)-carboxyfluorescein-N-hydroxysuccinimide ester (FLUOS)-conjugated A-BSA (GalNAc␣1,3Fuc␣1,2Gal␤-O-(CH 2 ) 8 CONH(CH 2 ) 2 NHCO(CH 2 ) 5 CO) n -NH-BSA (molecular weight of glycoconjugate ϭ 82 563 kDa, average sugar residues per protein molecule ϭ 19; Dextra, Reading, United Kingdom), and control FLUOS-conjugated BSA (Roche, Indianapolis, IN) were used. Fluorescein conjugation of A-BSA and BSA was performed using Fluorescein Protein Labeling kit (Roche) according to the manufacturer's instructions. 10 6 Spl or PerC cells per 100 L were incubated with 0.5 g/100L FLUOS-A-BSA or control FLUOS-BSA in a flow cytometry (FCM) medium (PBS containing 0.1% BSA and 0.1% sodium azide) for 1 hour at 4°C. The cells were further stained with biotin-conjugated anti-mouse IgM R6-60.2 (BD PharMingen, San Diego, CA), phycoerythrin (PE)-conjugated anti-mouse CD11b M1/70 (BD PharMingen), anti-mouse CD19 1D3 (BD PharMingen), or anti-mouse CD5 53-7.3 (BD PharMingen) mAb to classify B-cell subsets. The biotinylated mAb were visualized using allophycocyanin-streptavidin. Four-color FCM was performed on a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA). Nonspecific Fc ␥receptor binding of labeled Abs was blocked by anti-mouse CD16/32 2.4G2 (BD PharMingen). An isotype-matched irrelevant mAbs were used as a control. Dead cells were excluded from the analysis based on light scatter and staining with propidium iodide.
ELISA assays
Total mouse Igs and anti-A-specific Abs (including IgG and IgM) levels in sera were determined by enzyme-linked immunosorbent assay (ELISA) as described previously. 13, 20 Briefly, ELISA plates were coated with 5 g/mL of goat anti-mouse Ig (IgGϩIgMϩIgA, heavy chain ϩ light chain; Southern Biotechnology, Birmingham, AL), 5 g/mL synthetic A-BSA (Dextra) or control BSA (Roche). Diluted serum samples were incubated in the plates, and bound Abs were detected using horseradish peroxidaseconjugated goat anti-mouse IgG/IgM-specific Abs (KPL, Guilford, United Kingdom). Color development was achieved using 0.1 mg/mL Ophenylenediamine (Sigma, St Louis, MO) in a substrate buffer. The reaction was stopped by the addition of 3 M H 2 SO 4, and absorbance was measured at 492 nm. Anti-A-specific Ab levels were determined by subtracting the absorbance of wells coated with control BSA from the absorbance of wells coated with A-BSA. Purified mouse IgG (Zymed, South San Francisco, CA) and IgM (ICN Pharmaceuticals, Aurora, OH) were used as standard controls. 
FCM analysis of anti-human RBC Abs
ELISPOT for detecting anti-A Ab-producing cells
Enzyme-linked immunospot (ELISPOT) assay to detect anti-A Abproducing cells was performed as described previously. 21 Briefly, nitrocellulose membranes of a 96-well filtration plate (Millipore, Bedford, MA) were coated with 5 g/mL A-BSA or control BSA for detecting anti-A IgM/IgG-producing cells. Nonspecific binding sites were blocked using 0.4% BSA in Iscove modified Dulbecco medium (IMDM; Sigma). Serial dilutions of cell suspension in IMDM supplemented with 0.4% BSA, 5 g/mL insulin (Sigma), 5 g/mL transferrin (Sigma), 5 ng/mL sodium selenite (Sigma), 50 M 2-mercaptoethanol, and 1 g/mL gentamicin were added to triplicate wells. After 24 hours of culture at 37°C, bound Abs were detected using horseradish peroxidase-conjugated goat anti-mouse IgM/ IgG Abs (Southern Biotechnology), followed by color development with 3-amino-9-ethyl carbazole (Sigma). After the membranes were dried the wells of 96-well filtration plates for ELISPOT assay were observed using a Leica MZ6 microscope (Leica, Wetzler, Germany; magnification 10ϫ/0.63), and the photos of those wells were taken by a Nikon COOL PIX 950 digital camera (Nikon, Tokyo, Japan). The photo data were visualized using Abode Photoshop 6.0 (Adobe Systems, San Jose, CA).
In vitro B-cell proliferation assay
The resting B cells were isolated from splenocytes of untreated Balb/c mice by negative selection using a B-cell isolation kit and auto-magnetic-associated cell sorter (MACS) (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. Then, the B cells were labeled with 5 M 5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) as described previously. 22 The CFSE-labeled cells were cultured in Roswell Park Memorial Institute (RPMI; Nacalai Tesque, Kyoto, Japan) culture medium containing 10% fetal bovine serum (Sanko, Tokyo, Japan), 5 M 2-mercaptoethanol (Katayama, Osaka, Japan), 1% HEPES buffer (GIBCO, Grand Island, NY), and 100 IU/mL penicillin-100 g/mL streptomycin (GIBCO). The following stimuli were added at the start of the culture: 10 g/mL of goat anti-mouse IgM F(abЈ) 2 (Jackson ImmunoResearch Laboratories, West Grove, PA), 1 g/mL recombinant mouse CD40L, and 1 g/mL enhancer (Alexis Cor, Lausen, Switzerland), as well as 0.02 g/mL recombinant mouse IL-4 (R&D Systems, Minneapolis, MN). In the CsA inhibition assay, various doses of CsA (6.25-100 ng/mL; which was kindly provided by Novartis, Basel, Switzerland) were added at the start of the culture. The cultures were incubated at 37°C in a 5% CO 2 for 3 days. The cultivated cells were stained with PE-conjugated CD19 1D3 (BD PharMingen) or biotinylated CD5 53-7.3 mAb (BD PharMingen). The biotinylated mAb were visualized using allophycocyanin-streptavidin.
In vitro depletion of anti-A Ab producing cells by using A-BSA, anti-BSA Abs, and complement Spl cells (10 ϫ 10 7 /mL) from Balb/c mice that had received an intraperitoneal injection of 5 ϫ 10 8 A-RBCs (8 days prior to analysis) were cultured in IMDM supplemented with 0.4% BSA in the presence of various concentrations of A-BSA (6.125-200g/mL) for 30 minutes, then incubated with 50-fold diluted rabbit anti-BSA Abs (ICN Pharmaceuticals, Aurora, Ohio) for 30 minutes, followed by incubation with 25-fold diluted rabbit complement (Cedarlane, Burlington, ON) for 15 minutes. Finally, all cells were subjected to ELISPOT assay to determine the frequency of anti-A IgM-producing cells.
In vivo treatment using A-BSA, anti-BSA Abs, and/or CsA Balb/c mice received an intraperitoneal injection of A-BSA diluted in PBS at a dose of 200 g/mouse. After 6 hours, the mice received an intraperitoneal injection of rabbit anti-BSAAbs that had been diluted 20-fold in PBS at a dose of 1 mL/mouse. As indicated, CsA was daily administered intraperitoneally at various doses (5-50 mg/kg/day). Untreated mice and mice receiving injections of either A-BSA or CsA alone were used as controls.
Statistical analysis
The results were statistically analyzed using the unpaired Student t test of means or analysis of variance (ANOVA). A P value of less than .05 was considered statistically significant.
Results
Normal mice possess B cells with receptors for blood group A determinants, which show sIgM high CD11b ؉ CD5 ؉ B-1 phenotype in the peritoneal cavity, and IgM ؉ CD11b ؊ CD5 ؊ B-2 phenotype in the spleen ABO histo-blood group Abs are thought to be developed following trisaccharide-specific immune stimulation by environmental bacteria that express these carbohydrate determinants. [23] [24] [25] [26] Consistent with the accepted belief that the response of the B-cell compartment to microbial products is derived preferentially from the activation of CD5 ϩ B-1 cells, [27] [28] [29] we recently demonstrated that B cells with receptors for blood group A carbohydrate determinants were found exclusively in a sIgM ϩ CD11b ϩ CD5 ϩ B-1 subpopulation in blood group O or B human peripheral blood. 13 Previous experiments by us and other researchers showed significant levels of naturally occurring anti-human blood group A-determinant Abs but undetectable levels of anti-human blood group B-determinant Abs in the sera from several strains of mice. 13, 23, 30, 31 The absence of 
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Anti-A Ab-producing cells are localized predominantly in the spleen
Next, we determined the anatomical location of the cells that actively produce anti-A Abs. In mice that were either nonimmunized or immunized with an intraperitoneal injection of 5 ϫ 10 8 A-RBCs, the frequency of anti-A Ab-producing cells was quantified 7 days after the immunization by ELISPOT assay of the suspended cells from various tissues including Spl, bone marrow (BM), PerC, cervical lymph nodes, and mesenteric lymph nodes. Anti-A IgM-producing cells were localized mainly in the Spl, and were detectable in the BM, but not in the PerC (Figure 1C) , cervical lymph nodes, and mesenteric lymph nodes (data not shown). After immunization with A-RBCs, red spots formed due to Ab production increased both in number and size in the Spl, indicating the enhanced frequency and activity of anti-A IgM-producing cells at this site ( Figure 1C) . No anti-A IgG-producing cells were detected at any tested sites, even after A-RBC immunization at this time point (data not shown).
CsA blocked CD5 ؉ B-1 cell differentiation induced by sIgM cross-linking but not B-2 cell differentiation by CD40 ligation
It has been recently demonstrated that PerC B-1 cells are precursors of splenic IgM Ab-producing cells, 33 and the PerC B-1 cells are differentiated through Ig gene rearrangement following stimulation with TI-2 Ags. 14-17 A previous report supports the claim that such B-1 cell differentiation can be blocked by CsA treatment. 18 To verify this hypothesis, resting B cells isolated from splenocytes of Balb/c mice were treated with anti-IgM F(abЈ) 2 , an analog of TI-2 Ags, or CD40L and IL-4, which provide thymus-dependent inductive signals in the presence or absence of CsA in vitro. Prior to these treatments, resting B cells were labeled with CFSE, thereby allowing phenotypic analysis of the proliferating cells by multicolor FCM analysis. CD19 ϩ B cells stimulated with anti-IgM F(abЈ) 2 or with CD40L/IL-4 vigorously proliferated after 3 days in culture; however, only the former developed into CD5 ϩ B cells. Proliferating B cells induced by CD40L/IL-4 lacked CD5 expression. The limited proportion of nonstimulated/nonproliferating spontaneous B cells that express CD5 might be the cells that have already differentiated to B-1 cells prior to the culture. CsA added at the start of culture inhibited B-cell proliferation induced by anti-IgM F(abЈ) 2 ; however, it had no effect on CD40L/IL-4 induced B-cell proliferation (Figure 2A) . A clinically relevant concentration of CsA (100 ng/mL) completely blocked CD5 ϩ B-cell proliferation ( Figure 2B ). In the PerC of mice treated with CsA for 2 weeks, the proportion of IgM high CD11b ϩ CD5 ϩ B-1a cells exclusively decreased in a dose-dependent manner. The inhibitory effect of CsA on B-1a cells was obvious even at a clinically relevant dose (5-50 mg/kg/day; Table 1 ). The total number of PerC B cells obtained from a mouse was constant regardless of CsA doses (ranging from 5 ϫ 10 6 /mouse to 8 ϫ 10 6 /mouse), and the proportion of sIgM ϩ CD5 Ϫ CD11b Ϫ B-2 cells was conversely elevated. These findings are consistent with the results of the in vitro study demonstrating that CsA blocks the differentiation from B-2 cells to B-1a cells but does not affect B-2 cells per se, although we cannot exclude the possibility that CsA treatment influences the migration of certain subsets of B cells from/to the PerC.
In vitro depletion of anti-A IgM-producing cells by A-BSA/anti-BSA Abs
The ability of A-BSA and rabbit anti-BSA Abs (A-BSA/anti-BSA Abs) to deplete anti-A IgM-producing cells was studied in vitro. Balb/c mice were twice immunized with 5 ϫ 10 8 A-RBCs at a 1-week interval. Spl cells prepared from the mice 7 days after the second immunization were incubated with various concentrations of A-BSA, and then incubated with rabbit anti-BSA Abs, followed by incubation with rabbit complement. Subsequently, the cells were subjected to ELISPOT assay for determining the frequency of anti-A IgM-producing cells. Incubation of the Spl cells with 10 g/mL of A-BSA, anti-BSA Abs, and complement almost completely eliminated anti-A IgM-producing cells, but no significant depletion of these cells was observed when the Spl cells were incubated with rabbit anti-BSA Abs and complement alone ( Figure  3A ). A linear relationship was observed between the frequency of the remaining anti-A IgM-producing cells after A-BSA/anti-BSA Abs treatment and the logarithmic concentration of the used ( Figure 3B ). These findings indicate that A-BSA binding to specific anti-A sIgM on the B cells followed by anti-BSA binding leads to complement activation, resulting in specific toxicity against these B cells.
Persistent reduction of anti-A IgM levels in sera from mice that received A-BSA/anti-BSA Abs and CsA
The ability of A-BSA/anti-BSA Abs to deplete anti-A IgMproducing cells was next studied in vivo. Balb/c mice were injected with A-BSA followed by rabbit anti-BSA Abs; however, these mice did not receive exogenous administration of complement because they are competent with regard to complementmediated cytotoxicity. In mice that received the A-BSA/anti-BSA Ab injection, the anti-A IgM serum levels were reduced on day 1, and remained low until day 14 ( Figure 4 ), whereas in untreated control mice, these levels gradually increased during the observation period. This is consistent with the age-related increase in mouse naturally occurring Abs as described previously. 34 No reduction, but rather a slight increase in the anti-A IgM levels, was observed in mice that had received only the A-BSA injection, eliminating the possibility that the reduction in anti-A Abs observed in the mice treated with A-BSA/anti-BSA Abs was merely due to adsorption by the corresponding carbohydrate epitopes of the injected A-BSA. Immunization with an intraperitoneal injection of 5 ϫ 10 8 A-RBCs facilitated anti-A IgM production in the untreated control mice. A similar CD5 ϩ B-1a cells exclusively decreased, but CD5 Ϫ B-2 increased in the PerC of the mice treated with CsA. After 2 weeks daily intraperitoneal injection of various doses of CsA into Balb/c mice, peritoneal cavity cells were harvested and stained with mAbs against B220 (RA3-6B2), CD11b (M1/70), and CD5 (53-7.3) to determine B-cell subsets (B-1a, B220 ϩ CD11b ϩ CD5 ϩ , B-1b, B220 ϩ CD11b ϩ CD5 Ϫ , B-2, and B220 ϩ CD11b Ϫ CD5 Ϫ . B-1a cells have been well defined as CD19 ϩ B220 ϩ sIgM ϩ CD11b ϩ CD5 ϩ cells. Since B220 ϩ CD11b ϩ CD5 ϩ cells universally expressed both sIgM and CD19, and sIgM ϩ CD11b ϩ CD5 ϩ cells universally expressed both CD19 and B220 in our previous studies, we considered both B220 ϩ CD11b ϩ CD5 ϩ cells and sIgM ϩ CD11b ϩ CD5 ϩ cells as B-1a cells. All mAbs were purchased from BD PharMingen). Mean percentages (Ϯ SEM) are shown. Figure 2 , CsA might be able to inhibit such replenishment by blocking B-1 cell differentiation. Consistent with this assumption, when CsA treatment and A-BSA/anti-BSA Ab treatments were combined, the anti-A Ab serum levels at 3 weeks after A-BSA/anti-BSA Ab injection were completely undetectable by ELISA. In addition, anti-A Ab-producing cells were undetectable in the Spl even after immunization with A-RBCs (Figure 4 ). CsA treatment (10 mg/kg per day) alone neither reduced the anti-A Ab serum levels nor inhibited anti-A Ab production in response to immunization with A-RBCs; this finding suggests that CsA does not affect preexisting Ab-producing cells. The reduction of anti-A Ab levels in the sera of mice treated with a combination of A-BSA/anti-BSA Abs and CsA was also confirmed by FCM analysis at 10 weeks after A-BSA/anti-BSA Ab injection. At this time point, the response to group A determinants was significantly reduced, but response to other human RBC antigens was preserved at normal levels in mice treated with A-BSA/anti-BSA Abs and CsA. This indicates the specificity of our approach to the correspondent blood group antigens ( Figure 5 ). In addition, the total serum IgM and IgG levels were maintained at normal levels in these mice (data not shown). We hypothesized that the synthetic A/B trisaccharide might be capable of not only removing anti-A/B Abs from sera but also targeting B cells that recognize A/B carbohydrate epitopes for specific elimination. We have previously demonstrated that all IgM-producing cells as well as their precursor B-1 cells express high levels of BCRs (sIgM) in mice. 19 This was indicated by the finding that all IgM-producing cells were eliminated in vitro from Spl cells when sIgM-expressing cells were depleted by FCM sorting using anti-IgM mAbs. In our preliminary study, similar results were observed in humans (data not shown). The presence of BCRs on IgM-producing cells suggests that cells For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From producing a particular IgM could be targeted for specific elimination by interaction with their BCRs and corresponding antigenic epitopes. Consistent with this assumption, it has been reported that B cells responding to a major xenogenic antigen, Gal, could be targeted for specific elimination by the toxin ricin A coupled to Gal epitopes. 35 Instead of using a toxin complex, which per se is an immunogenic substance with dose-limiting toxicities possibly including vascular leak syndrome, thrombocytopenia, and hepatic damage, we used nontoxic A carbohydrates conjugated to BSA. (Figures 4-6 ). Based on our recent demonstration that PerC CD11b ϩ B-1 cells are precursors of splenic IgM-producing cells, 33 and those by other researchers that the PerC B-1 cells are differentiated through Ig gene rearrangement following stimulation with TI-2 Ags (the induced differentiation hypothesis), [14] [15] [16] [17] it is conceivable that B-1 cells specific for A carbohydrates, even after their transient depletion, might newly develop from precursor B cells through V(D)J recombination due to stimulation with A carbohydrates. B-cell responses to CsA in vivo and in vitro is reported to block TI-2 stimulation, 16, 36 Furthermore, B-1 cell differentiation following stimulation with TI-2 Ags can be blocked by CsA treatment. 18 Since CsA suppresses the action of the nuclear factor, which is required for V(D)J recombination in precursor B cells, 37, 38 it might selectively affect precursors of B-1 cells. However, it may not affect well-differentiated B-1 cells or B cells that are actively producing Abs because these cells no longer require V(D)J recombination. This possibility would explain mechanisms underlying our findings that specific elimination of both Ab-producing cells and B-1 cells with anti-A specificity and subsequent CsA therapy lead to lasting inhibition of Ab production specific for A carbohydrates.
Reduction in B cells
Although survival rates of ABO-incompatible organ allografts have consistently improved with the improving B-cell and antibody-directed immunosuppressive therapies currently available, they remain inferior to those of ABO-compatible transplantation. One-year graft survival rates of approximately 50% to 60% following cadaveric ABO-incompatible kidney, liver, or heart transplantation, compared with 70% to 80% for an ABO-compatible organ, have been reported. 39 However, ABOmismatched liver and heart transplantation shows improved results in infants and young children compared with adults. [39] [40] [41] Human infants manifest several aspects of immunologic immaturity, notably deficiency of humoral responsiveness to stimulation with carbohydrate TI-2 antigens. 42 This includes development of isohemagglutinins or "natural" antibodies to nonself A/B blood group antigens, which remain low during the first months of life. 43, 44 On a trial of ABO-incompatible heart transplantation in infants, there were no cases of hyperacute or acute humoral rejection, nor clinical problems attributable to blood group incompatibility under the standard immunosuppression without splenectomy. 41 Analysis of the peripheral blood B cells from patients who had received ABO-incompatible heart grafts in their infancy showed that these cells were simultaneously incapable of producing antibodies against donor type A or B blood group antigens, yet produced antibodies against nondonor polysaccharides. Moreover, B lymphocytes with BCRs specific for donor-type A and B antigens were absent. These data suggest that anergy does not have a role in this setting, and that antigen-specific B cells are tolerized by deletion or receptor editing. 45 A similar tolerant state among A Ag-specific B cells has also been observed following blood group A-to-O pediatric liver transplantation. 46 However, it is important to note that in this setting, almost every recipient tolerant to donor type A/B antigens was treated with calcineurin inhibitors to prevent T-cell-mediated rejection of allografts. Consistent with our findings that calcineurin inhibitors block segregation to CD5 ϩ B-1a cells, the proportion of B-1a cells in peripheral blood was significantly reduced in patients persistently taking either CsA or tacrolimus in our preliminary study (data not shown). Since B-1 cells specific for blood group A/B carbohydrates are thought to be developed upon stimulation by gastrointestinal bacteria during maturation, 43 cell differentiation might be suppressed under the cover of calcineurin inhibitors. Such an interpretation would be involved in mechanisms for the development of B-cell tolerance to donor blood group A/B antigens after ABOincompatible heart or liver transplantation during infancy.
In conclusion, B cells with receptors for A carbohydrates, which belong to the CD5 ϩ CD11b ϩ B-1a subset, were temporarily eliminated by injecting synthetic A carbohydrates conjugated to BSA and anti-BSA Abs. Subsequent treatment with CsA, which blocks the B-1a cell differentiation, completely inhibited the reappearance of these B cells. This strategy thereby persistently prevented anti-AAb production, while maintaining normal serum Ig levels.
